The World Health Organization (WHO) issued a scathing formal statement on Friday, February 13, 2026, condemning a planned U.S.-funded clinical trial in Guinea-Bissau that seeks to study the effects of the hepatitis B vaccine on newborns. The agency, led by Director-General Tedros Adhanom Ghebreyesus, characterized the study as "unethical" and a violation of established scientific principles. The controversy centers on the trial's design, which involves withholding the proven, life-saving hepatitis B birth dose from a control group of infants in a country where the disease is highly prevalent.
According to the WHO, the trial is funded by the U.S. Centers for Disease Control and Prevention (CDC) under the direction of U.S. Health Secretary Robert F. Kennedy Jr. The CDC reportedly awarded $1.6 million to researchers from the University of Southern Denmark to conduct the study. The research aims to investigate "non-specific effects" of the vaccine, including alleged links to neuro-developmental disorders—claims that the WHO and the broader medical community maintain are unsupported by credible evidence. The trial was slated to involve 14,000 newborns in Guinea-Bissau, a West African nation where more than 12% of adults live with chronic hepatitis B.
The ethical breach, as defined by the WHO, lies in the "no-treatment" arm of the study. In Guinea-Bissau, the current national schedule administers the first dose at six weeks, though the government formally decided in 2024 to introduce the birth dose by 2028. The U.S.-funded researchers argued the trial was ethical because it compared the birth dose to the existing local standard of care. However, the WHO countered that "exploiting scarcity" is not a valid ethical justification for withholding a known life-saving intervention. The agency emphasized that the birth dose is 70% to 95% effective in preventing mother-to-child transmission, and delaying it exposes infants to irreversible risks of cirrhosis and liver cancer.
This confrontation marks a significant escalation in the ideological divide between the U.S. government and global health authorities. Since U.S. President Trump took office in January 2025, the administration has moved to overhaul domestic and international health policies. This includes the recent decision by a U.S. advisory panel to stop recommending universal hepatitis B vaccination for newborns in the United States. Furthermore, the U.S. has already issued its one-year notice of withdrawal from the WHO, a move that Kennedy defended by claiming the organization has failed to respect American contributions.
From a public health perspective, the implications of this trial extend far beyond the borders of Guinea-Bissau. By funding research that questions the safety of a vaccine used globally for over four decades, the U.S. administration risks undermining confidence in immunization programs worldwide. Data from the WHO indicates that transmission at birth is the primary driver of lifelong hepatitis B infection; approximately 90% of infants infected during childbirth become chronic carriers. Undermining the birth dose recommendation could stall or reverse decades of progress in eliminating the virus as a global health threat.
The suspension of the trial by the government of Guinea-Bissau, pending further technical and ethical reviews, suggests that international pressure and scientific consensus still hold weight in sovereign decision-making. However, the forward-looking trend suggests a fragmented global health landscape. As the United States—traditionally the largest donor to global health initiatives—pivots toward a more skeptical stance on vaccines and international cooperation, other nations and organizations like the WHO will face increasing challenges in maintaining unified standards for medical research and disease prevention.
Ultimately, the Guinea-Bissau case serves as a harbinger of a new era in global health diplomacy, where political ideology increasingly challenges established medical ethics. The outcome of the pending reviews in Guinea-Bissau will likely set a precedent for how developing nations navigate the influence of major powers against the guidelines of international health bodies. For now, the medical community remains on high alert, fearing that the politicization of vaccine science could lead to a resurgence of preventable diseases in the world's most vulnerable regions.
Explore more exclusive insights at nextfin.ai.
